Breaking News

02 July 2015. The monoamine oxidase B inhibitor sembragiline missed its primary endpoint in a Phase 2b trial for Alzheimer’s disease. Researchers will analyze secondary endpoints. See news.


This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at


Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

Further Reading


  1. Enter Aη: Alternative APP Cleavage Creates Synaptotoxic Peptide
  2. Can Exercise Slow the Progression of Alzheimer’s Pathology?
  3. Exercise Boosts Cognition In Symptomatic Disease
  4. Prion Stabilizers Boost Survival in Infected Mice—What About Other Proteinopathies?


  1. Computational Modeling—Will it Rescue AD Clinical Trials?
  2. Resolving Controversies on the Path to AD Therapeutics
  3. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
  4. Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery

Other Resources

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources